CAMBRIDGE, Mass., July 16, 2026
Moderna, Inc. has announced the first participant has been dosed in its Phase 1 clinical trial evaluating mRNA-4200, an investigational tumor-targeted cancer antigen therapy, in adults with advanced or metastatic solid tumors. The milestone marks another significant advancement in Moderna’s expanding mRNA oncology pipeline, as the company continues to develop innovative off-the-shelf cancer immunotherapies designed to activate the immune system against multiple tumor types. Unlike therapies that target a single tumor antigen, mRNA-4200 encodes seven shared tumor antigens commonly found across different cancers, aiming to stimulate broad and durable T-cell immune responses against malignant cells. The first dose was administered at START Mountain Region in Salt Lake City, Utah, as part of a multicenter Phase 1 study evaluating the therapy in combination with checkpoint inhibitor treatment. This achievement underscores Moderna’s commitment to advancing next-generation mRNA medicines beyond infectious diseases into precision oncology and highlights growing momentum in the development of innovative immunotherapies for patients with difficult-to-treat cancers.
mRNA-4200 Expands Moderna’s Cancer Immunotherapy Pipeline
mRNA-4200 represents Moderna’s third off-the-shelf cancer antigen therapy candidate, reflecting the company’s strategy to develop scalable mRNA-based cancer treatments capable of addressing multiple tumor types. The investigational therapy is engineered to encode seven tumor-associated antigens frequently shared across patients, enabling activation and expansion of tumor-specific T cells that recognize and attack cancer cells. By targeting several cancer-associated antigens simultaneously, the therapy seeks to overcome one of the major limitations of single-target immunotherapies while potentially reducing the likelihood of tumor immune escape. Moderna believes this multi-antigen approach could broaden the applicability of mRNA immunotherapy across a wide range of solid tumors and strengthen long-term anti-cancer immune responses. The company continues to leverage its proprietary mRNA platform technology to develop therapies capable of delivering complex biological instructions directly within the body, opening new opportunities for personalized and universal cancer treatment strategies.
Phase 1 Trial Evaluates Safety and Combination Therapy
The ongoing Phase 1 clinical trial (NCT06880549) is an open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, and preliminary clinical activity of mRNA-4200 when administered alongside checkpoint inhibitor therapy in adults with advanced or metastatic solid tumors. Researchers will assess multiple dose levels to establish an appropriate safety profile while monitoring immune activation and potential anti-tumor responses. The study represents an important first step in determining whether the investigational therapy can safely generate robust immune responses against multiple shared tumor targets in patients with advanced cancers. The trial also reflects Moderna’s broader strategy of combining mRNA-based therapeutics with established immuno-oncology approaches to maximize therapeutic effectiveness. Successful completion of this early-stage study could pave the way for expanded clinical development across multiple oncology indications where durable immune activation remains an unmet medical need.
Advertisement
Strategic Collaboration Advances Next-Generation Oncology Innovation
The development of mRNA-4200 is supported through Moderna’s collaboration with Immatics, utilizing the company’s XPRESIDENT® target discovery platform and XCUBE® bioinformatics and artificial intelligence technologies to identify clinically relevant tumor antigens. This partnership combines advanced computational biology with Moderna’s proven mRNA technology platform, accelerating the development of innovative cancer immunotherapies designed to improve patient outcomes. As global interest in mRNA oncology continues to grow following the success of mRNA vaccines, Moderna is expanding its research portfolio to include therapies targeting infectious diseases, rare diseases, and cancer. The initiation of patient dosing in the Phase 1 study marks an important milestone in translating advanced mRNA-based immunotherapy into clinical practice and reinforces the company’s long-term vision of transforming cancer treatment through precision medicine. If future clinical studies confirm the therapy’s safety and efficacy, mRNA-4200 could contribute to a new generation of broadly applicable cancer immunotherapies capable of treating multiple solid tumor types.
Source: Moderna press release
